Kestra Medical (KMTS) CFO Mahboob Vaseem Sells Shares

What Happened
Mahboob Vaseem, Chief Financial Officer of Kestra Medical Technologies, sold a total of 6,995 shares in two open-market transactions on August 4, 2026, generating about $172,635 in proceeds. The reported trades were: 3,080 shares at a weighted average price of $24.06 (proceeds $74,096) and 3,915 shares at a weighted average price of $25.17 (proceeds $98,539). These were sales (not purchases), and at least some shares were sold to cover tax withholding tied to RSU vesting.

Key Details

• Transaction dates: August 4, 2026; Form 4 filed August 6, 2026 (appears timely).
• Reported sale amounts and prices:
  • 3,080 shares — weighted avg $24.06; price range reported $23.9030–$24.4200 (F2). Proceeds ≈ $74,096.
  • 3,915 shares — weighted avg $25.17; price range reported $25.0000–$25.3800 (F4). Proceeds ≈ $98,539.
• Total shares sold: 6,995; total proceeds ≈ $172,635.
• Shares owned after the transaction: not provided in the data you supplied.
• Notable footnotes:
  • F1: Sales include nondiscretionary "sell-to-cover" transactions to satisfy tax withholding for RSU vesting.
  • F3: Transactions were made under a prearranged Rule 10b5-1 trading plan adopted Nov 6, 2025.
  • F2/F4: Reported column prices are weighted averages; per-share sale prices fall within the ranges above. Additional per-price details are available upon request.
• Filing timeliness: Form 4 filed two days after the trades (Aug 6 vs Aug 4), consistent with normal reporting timing.

Context
Sell-to-cover transactions and trades executed under 10b5-1 plans are common for insiders realizing vested equity and typically reflect tax-management or prearranged actions rather than a discretionary view of the company. Because these were sales (not purchases) and were partly to satisfy tax obligations, they do not necessarily signal management sentiment about Kestra Medical’s outlook.